- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04685590
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study (SToMP-AD)
December 13, 2023 updated by: Wake Forest University Health Sciences
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease
The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
This study is a Phase II multi-site, randomized, double-blind placebo controlled trial to determine safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive.
Study Type
Interventional
Enrollment (Estimated)
48
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Miranda Orr, PhD
- Phone Number: 336-713-8830
- Email: morr@wakehealth.edu
Study Contact Backup
- Name: Sarah B Bohlman, MSL
- Phone Number: 336-716-7354
- Email: sarabrow@wakehealth.edu
Study Locations
-
-
-
Barcelona, Spain
- Not yet recruiting
- Fundación ACE Clinical Site
-
Principal Investigator:
- Merce Boada Rovira
-
Contact:
- Mercé Boada Rovira
-
Barcelona, Spain
- Not yet recruiting
- Hospital Clínic de Barcelona Site
-
Contact:
- Raquel Sánchez del Valle
- Email: rsanchez@clinic.cat
-
Principal Investigator:
- Raquel Sánchez del Valle
-
Barcelona, Spain
- Not yet recruiting
- Sant Pau Clinical Site
-
Contact:
- Rafael Blesa González
- Email: rblesa@santpau.cat
-
Principal Investigator:
- Rafael Blesa González
-
Sevilla, Spain
- Not yet recruiting
- FISEVI Clinical Site
-
Contact:
- Emilio Franco Macías
- Email: efranco17@gmail.com
-
Principal Investigator:
- Emilio Franco Macías
-
-
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest Health Sciences
-
Contact:
- Miranda Orr, PhD
- Phone Number: 336-713-8830
- Email: morr@wakehealth.edu
-
Contact:
- Sarah B Bohlman, MSL
- Phone Number: 336-716-7354
- Email: sarabrow@wakehealth.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
63 years and older (Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Ages 65 years and older at screening
- Both sexes
- All ethnicities
- Diagnosis of amnestic mild cognitive impairment (aMCI) or early Alzheimer's disease (AD)
- Elevated tau protein as determined by CSF Aβ:tau ratio
- FDA-approved medications for AD (e.g. donepezil, rivastigmine, galantamine) are permitted as long as the participant has been maintained on a stable dose for at least three months prior to study entry.
- Labs: Normal blood cell counts, normal liver and renal function without clinically significant excursions as determined by coordinating center Medical Monitor. Total cholesterol <240 mg/dl, HbA1c ≤ 7%.
- prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) within normal limits
- Participants must have the ability to provide written consent or be accompanied by a Legally Authorized Representative designated to sign informed consent (if determined not to have decision capacity by Site PI).
- Participants must have a study partner who agrees to participate throughout the duration of the study. The study partner must have frequent and sufficient contact (approximately 10 hours per week) with the participant and be able to provide accurate information regarding the participant's cognitive and functional abilities.
- Participants must have no travel plans that would interfere with scheduling visits following consent over the 12 months of study duration
- Must speak English fluently and have at least six years of formal education
Exclusion Criteria:
- Body mass index (BMI)>40 kg/m2
- corrected QT interval (QTc) >450 msec
- MRI contraindications including claustrophobia, the presence of metal (ferromagnetic) implants, or cardiac pacemaker.
- Pregnancy
- Any significant neurologic disease other than prodromal or early AD including Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
- Current or history of alcohol or substance abuse or dependence within the past 2 years Diagnostic and Statistical Manual of Mental Disorders (DSM V criteria)
- Uncontrolled diabetes (HbA1c > 7% or the current use of insulin or sulfonylureas)
- Poorly controlled blood pressure (systolic BP>160, diastolic BP>90 mmHg)
- eGFR < 10 ml/ min/ 1.73 m2.
- Myocardial infarction, angina, stroke, or transient ischemic attack in the past 6 months.
- Chronic heart failure.
- Presence of significant liver disease with total bilirubin >2X upper limit.
- Inability to tolerate oral medication.
- Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus, or sirolimus).
- Subjects currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy.
- Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.) other than low-dose aspirin
- Subjects taking H2 antagonists or proton pump inhibitors who are unable or unwilling to reduce or hold therapy for at least 2 days prior to and during each of the 2-day courses of Dasatinib plus quercetin dosing. Instead, subjects may use antacids prior to and during each of the 2-day courses of Dasatinib plus quercetin dosing.
- Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of study drug or placebo: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, thyroid hormones, eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacrolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, warfarin, heparin, full dose ASA, clopidogrel, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron, riluzole.
- Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Dasatinib (D) is given as (1) 100mg capsule daily for 2 consecutive days (Sprycel®, Bristol Myers Squibb).
Quercetin (Q) will be given as (4) 250 mg capsules daily (total 1000 mg daily) for the same 2 consecutive days (Thorne Research).
Both are administered orally.
|
D+Q will be administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
|
Placebo Comparator: Placebo
Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
|
Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serious Adverse Events (SAEs) and Adverse Events (AEs) in treatment group as compared to placebo group
Time Frame: Baseline to Week 48
|
Adverse Events (AEs) and SAEs will be collected at each in-person visit and at scheduled telephone visits from baseline to week 48.
Incidence of SAEs between groups (treatment vs. placebo) will be reviewed by the Data Safety Monitoring Board (DSMB) for clinical significance.
|
Baseline to Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cellular senescence blood marker Senescence-Associated Secretory Phenotype (SASP) composite score
Time Frame: Baseline to Week 12
|
Composite score (average z-score of log-transformed values) of ten primary SASP factors measured in blood.
|
Baseline to Week 12
|
Change in cellular senescence blood marker Cluster of Differentiation 3 (CD3) in blood
Time Frame: Baseline to Week 12
|
Primary markers of cellular senescence CD3 measured in blood.
|
Baseline to Week 12
|
Change in cellular senescence blood marker cyclin-dependent kinase inhibitor 2A (p16INK4A+) in blood
Time Frame: Baseline to Week 12
|
Primary markers of cellular senescence p16INK4A+ measured in blood.
|
Baseline to Week 12
|
Change in cellular senescence blood marker T cells in blood
Time Frame: Baseline to Week 12
|
Primary markers of cellular senescence T cells measured in blood.
|
Baseline to Week 12
|
Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) slope
Time Frame: Baseline to Week 48
|
CDR is calculated on the basis of testing six different cognitive and behavioral domains such as memory, orientation, judgment and problem solving, community affairs, home and hobbies performance, and personal care.
The CDR is based on a scale of 0-3: no dementia (CDR = 0), questionable dementia (CDR = 0.5), MCI (CDR = 1), moderate cognitive impairment (CDR = 2), and severe cognitive impairment (CDR = 3).
The six domains are often summed to create a 0 - 18 "sum of the boxes" score.
CDR-SB has been shown to demonstrate sensitivity to cognitive changes associated with progression of amnestic mild cognitive impairment (aMCI) and early Alzheimer's Disease (AD).
|
Baseline to Week 48
|
Change in the 14 - item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 14) slope
Time Frame: Baseline to Week 48
|
A psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis.
A higher score indicates more impairment.
Scores from the original portion of the test range from 0 (best) to 65 (worse), and are added to the mean of the words not immediately recalled (max of 10) and the number of items not recalled after a delay (ranging from 0-10) all total the maximum score of 85.
A positive change indicates cognitive worsening.
|
Baseline to Week 48
|
Change in Positron Emission Tomography (PET) - Computed Tomography (CT) - brain tau pathology
Time Frame: Baseline to Week 48
|
Tau levels in the brain will measured by 18F AV1451 PET imaging to assess target engagement of dasatinib and quercetin (D+Q) and impact on brain tau as a relevant Alzheimer's Disease (AD) biomarker.
|
Baseline to Week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Miranda Orr, PhD, Wake Forest University Health Sciences
- Principal Investigator: Suzanne Craft, PhD, Wake Forest University Health Sciences
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gonzales MM, Krishnamurthy S, Garbarino V, Daeihagh AS, Gillispie GJ, Deep G, Craft S, Orr ME. A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials. Mech Ageing Dev. 2021 Dec;200:111589. doi: 10.1016/j.mad.2021.111589. Epub 2021 Oct 21.
- Guerrero A, De Strooper B, Arancibia-Carcamo IL. Cellular senescence at the crossroads of inflammation and Alzheimer's disease. Trends Neurosci. 2021 Sep;44(9):714-727. doi: 10.1016/j.tins.2021.06.007. Epub 2021 Aug 5.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 22, 2021
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 1, 2026
Study Registration Dates
First Submitted
December 22, 2020
First Submitted That Met QC Criteria
December 22, 2020
First Posted (Actual)
December 28, 2020
Study Record Updates
Last Update Posted (Estimated)
December 14, 2023
Last Update Submitted That Met QC Criteria
December 13, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Cognition Disorders
- Alzheimer Disease
- Cognitive Dysfunction
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protective Agents
- Protein Kinase Inhibitors
- Antioxidants
- Dasatinib
- Quercetin
Other Study ID Numbers
- IRB00067429
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RecruitingMild Cognitive Impairment (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute on Aging... and other collaboratorsCompletedMild Cognitive Impairment (MCI)United States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Meir Medical CenterTerminatedMild Cognitive Impairment (MCI)Israel
Clinical Trials on Dasatinib + Quercetin
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHead and Neck Squamous Cell CarcinomasChina
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Washington University School of MedicineUConn HealthRecruitingSchizophrenia | Treatment Resistant Depression | Aging, PrematureUnited States
-
The University of Texas Health Science Center at...Mayo ClinicCompletedAlzheimer DiseaseUnited States
-
TruDiagnosticActive, not recruiting
-
Mayo ClinicRecruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingNAFLD | Liver Fibrosis | NASH With FibrosisNetherlands
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingFrailty | Childhood CancerUnited States
-
Mayo ClinicEnrolling by invitation
-
Odense University HospitalNovo Nordisk A/S; Odense Patient Data Explorative NetworkRecruiting